

### Disclaimer and cautionary statement

The information contained in this presentation is not for use within any country or jurisdiction or by any persons where such use would constitute a violation of law. If this applies to you, you are not authorised to access or use any such information.

This presentation may contain "forward-looking statements" that are based on our current expectations, assumptions, estimates and projections about us and our industry. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain the words "may", "will", "should", "continue", "believe", "anticipate", "expect", "estimate", "intend", "project", "plan", "will likely continue", "will likely result", oxr words or phrases with similar meaning. Undue reliance should not be placed on such statements because, by their nature, forward-looking statements involve risks and uncertainties, including, without limitation, economic, competitive, governmental and technological factors outside of the control of SIG Group AG ("SIG", the "Company" or the "Group"), that may cause SIG's business, strategy or actual results to differ materially from the forward-looking statements (or from past results).

For any factors that could cause actual results to differ materially from the forward-looking statements contained in this presentation, please see our offering circular for the issue of notes in June 2020. SIG undertakes no obligation to publicly update or revise any of these forward-looking statements, whether to reflect new information, future events or circumstances or otherwise. It should further be noted that past performance is not a guide to future performance. Persons requiring advice should consult an independent adviser.

While we are making great efforts to include accurate and up-to-date information, we make no representations or warranties, expressed or implied, and no reliance may be placed by any person as to the accuracy and completeness of the information provided in this presentation and we disclaim any liability for the use of it.

Neither SIG nor any of its directors, officers, employees, agents, affiliates or advisers is under an obligation to update, correct or keep current the information contained in this presentation to which it relates or to provide the recipient of it with access to any additional information that may arise in connection with it and any opinions expressed in this presentation are subject to change.

The presentation may not be reproduced, published or transmitted, in whole or in part, directly or indirectly, to any person (whether within or outside such person's organisation or firm) other than its intended recipients.

The attached information is not an offer to sell or a solicitation of an offer to purchase any security in the United States or elsewhere and shall not constitute an offer, solicitation or sale any securities of SIG in any state or jurisdiction in which, or to any person to whom such an offer, solicitation or sale would be unlawful nor shall it or any part of it form the basis of, or be relied on in connection with, any contract or investment decision. No securities may be offered or sold within the United States or to U.S. persons absent registration or an applicable exemption from registration requirements. Any public offering of securities to be made in the United States will be made by means of a prospectus that may be obtained from any issuer of such securities and that will contain detailed information about us. Any failure to comply with the restrictions set out in this paragraph may constitute a violation of the securities laws of any such jurisdiction.

This presentation is not an offer to sell or a solicitation of offers to purchase or subscribe for securities. This document is not a prospectus within the meaning o the Swiss Financial Services Act nor a prospectus under any other applicable law.

In this presentation, we utilise certain alternative performance measures, including but not limited to EBITDA, adjusted EBITDA, adjusted EBITDA margin, net capex, adjusted net income, free cash flow and net leverage ratio that in each case are not defined in International Financial Reporting Standards ("IFRS").

These alternative non-IFRS measures are presented as we believe that they and similar measures are widely used in the markets in which we operate as a means of evaluating a company's operating performance and financing structure. Our definition of and method of calculating the measures stated above may not be comparable to other similarly titled measures of other companies and are not measurements under IFRS, as issued by the IASB or other generally accepted accounting principles, are not measures of financial condition, liquidity or profitability and should not be considered as an alternative to profit from operations for the period or operating cash flows determined in accordance with IFRS, nor should they be considered as substitutes for the information contained in our consolidated financial statements. You are cautioned not to place undue reliance on any alternative performance measures and ratios not defined in IFRS included in this presentation.

#### Alternative performance measures

For additional information about the alternative performance measures used by management (including reconciliations to measures defined in IFRS and the refined definitions of adjusted net income, free cash flow and net capital expenditure please refer to this link:

https://www.sig.biz/investors/en/performance/definitions

Some financial information in this presentation has been rounded and, as a result, the figures shown as totals in this presentation may vary slightly from the exact arithmetic aggregation of the figures that precede them.




## Overview 2022




### **Business Highlights**

### Implementing our strategy and driving growth









### Acquisitions of Scholle IPN and Evergreen Asia

Broadening leadership in sustainable packaging systems and solutions

Strong revenue performance from bag-in-box and spouted pouch

Integration progressing well with initial revenue synergies coming through

### Growth in all regions

Strong volume growth supplemented by price increases

Pricing momentum increasingly offsetting cost inflation

2023 price increases underway

### High demand for aseptic fillers

Strong level of filler placements – 91 fillers placed in 2022.

Continued strong demand into 2023

Positive leading indicator for future growth

### Investing in our global manufacturing presence

Commencement of commercial production of Mexican aseptic carton plant

Construction of Indian aseptic carton plant 2023 – 2024

### Management appointments

CTO: Gavin Steiner – former vice president global R&D packaging and technology at Nestlé

CSCO: lan Wood – now responsible for global supply chain and production of SIG's entire expanded product offering



### SIG continues to be an industry leader in sustainability

### ESG ratings – SIG consistently rated highly



is now a constituent of the FTSE4Good Index Series<sup>(1)</sup>, which is designed to measure the performance of companies demonstrating strong Environmental, Social and Governance (ESG) practices.




EcoVadis Platinum – Our 2022 Platinum rating from EcoVadis again puts SIG in the top 1% of businesses participating in its latest sustainability assessment.

### Delivering on our sustainability commitments

100% of aseptic carton business deemed eligible under EU taxonomy as helping customers to reduce their carbon emissions, following self-assessment; alignment underway with independent 3<sup>rd</sup> party.

New GHG emission targets – ambitious targets to reduce Scope 1, 2 and 3 emissions by 52% per litre packed by 2030 from a 2020 baseline for SIG Group

- includes bag-in-box, spouted pouch and chilled carton segments
- in approval process with Science Based Targets initiative.





### 2022 financial highlights

Strong revenue growth driven by volume and price

Revenue € 2.78 billion

+27.4%

constant

Up +8.0% constant currency organic<sup>(1)</sup>

Up +34.8% reported

Adjusted EBITDA

€ 652

million (2021: € 571 m)

Adjusted EBITDA margin 23.5% (2021: 27.7%)

Free cash flow<sup>(2)</sup>

€ 263

million (2021: € 258 m)

Leverage 3.1x (2021: 2.5x)

Adjusted net income<sup>(2)</sup>

€ 287

million (2021: € 266 m)

Adjusted earnings per share € 0.79 (2021: € 0.79)

Proposed dividend per share<sup>(3)</sup>

CHF 0.47

(2021: CHF 0.45) paid from foreign capital contribution reserves

ROCE<sup>(4)</sup> **27.3%**(2021: 31.0%)

<sup>(4)</sup> In the calculation of the ROCE EBITA as of 31 December 2022, adjusted EBITDA and depreciation of PP&E includes the adjusted EBITDA and depreciation of PP&E of Scholle IPN and Evergreen Asia from 1 January 2022.



<sup>(1)</sup> Organic growth represents SIG revenue growth at constant currency, excluding the impacts of the Scholle IPN and Evergreen Asia acquisitions.

<sup>(2)</sup> Refined free cash flow and adjusted net income definitions.

<sup>(3)</sup> Equivalent to a total pay-out of ~€182.5 million at 31 December 2022 exchange rate. Subject to shareholder approval.

### **Europe summary**

€ million	Q4 2022	2022	
Revenue	244	849	
Revenue growth <sup>(1)</sup>	21.9%	15.9%	
Organic revenue growth(1),(2)	3.9%	4.4%	
Adjusted EBITDA		201	
Adjusted EBITDA margin	(2)	23.7%	

Strong organic revenue growth reflects resilient volumes and price increases

- Volume performance driven by:
  - Hochwald mega-project ramp up from Q3
  - NCSD<sup>(3)</sup> on-the-go consumption with combismile rollout
  - Market share gains in liquid dairy in Spain as customers grow
  - Customer market share gains in Poland with new product launches
  - Good mix between private label and premium brands
     ensuring regional resilience

#### 2023:

- Deployment of 1st SIG NEO lines, including for plantbased milk alternative
- Strong pipeline of filler placements as a function of our sustainability offering



<sup>(1)</sup> At constant currency.

<sup>(2)</sup> Excluding the impact of Scholle IPN acquisition and adjusting for MEA JV consolidation.

<sup>(3)</sup> Noncarbonated soft drinks

### Middle East and Africa summary

€ million	Q4 2022	2022
Revenue	98	332
Revenue growth <sup>(1)</sup>	1.7%	22.6%
Organic revenue growth(1),(2)	1.7%	12.1%
Adjusted EBITDA	<i>{</i>	86
Adjusted EBITDA margin		26.0%

### Excellent sales growth in 2022

- Rebound of portion pack volumes in NCSD post COVID-19
- Liquid dairy growth in South Africa following drought in 2021
- Market growth and share gains in liquid dairy especially in Saudi Arabia, Egypt and South Africa
- Recycle for Good launched in Egypt: recycling initiative using mobile app to arrange collection

### 2023:

First filler placement in Pakistan with focus on selected customers and categories

<sup>(2)</sup> Adjusting for MEA JV consolidation.



<sup>(1)</sup> At constant currency.

### **APAC** summary

€ million	Q4 2022	2022	
Revenue	303	900	
Revenue growth <sup>(1)</sup>	44.1%	19.1%	
Organic revenue growth(1),(2)	17.1%	7.8%	
Adjusted EBITDA		279	
Adjusted EBITDA margin		31.0%	

CHINA - Resilient performance despite COVID-19 restrictions

- Record 10.6 BN aseptic sleeves produced in China
- Delivered growth in market affected by COVID-19 restrictions
- Customers restocked in Q4 as COVID-19 measures lifted and ahead of Chinese New Year in January 2023
- Good growth in soy milk and further expansion into plantbased milk alternatives in chilled and ambient
- 2023: Product launch with Yili for aluminium –layer–free (SIG's next generation project green)

SOUTHEAST ASIA - Record filler wins in SE Asia and India

- Now supplying all leading dairies and NCSD customers in India
- Further regional growth in liquid dairy with key global customers

#### 2023:

- Strong project pipeline to be delivered
- Construction of aseptic carton plant in India



<sup>(1)</sup> At constant currency

<sup>(2)</sup> Excluding the impact of paper mill divestment and Scholle IPN and Evergreen Asia acquisitions.

### New plant in India

### Expansion of global production network

- Construction of phase 1 to commence in 2023 and completion expected by Q4 2024 in city of Ahmedabad, state of Gujarat
- Printing and finishing of aseptic carton packs
- Provides capacity for local supply for our rapidly expanding base of fillers in India
- Initial capacity up to 4 billion packs; ~€60 million investment in production related equipment
- Lease of land and buildings ~€30 million NPV estimate





### **Americas summary**

€ million	Q4 2022	2022
Revenue	222	697
Revenue growth <sup>(1)</sup>	96.0%	66.4%
Organic revenue growth(1),(2)	13.1%	11.5%
Adjusted EBITDA		141
Adjusted EBITDA margin	3	20.2%

### Exceptional revenue growth

- Continued market share gains in dairy in Mexico and Brazil with regional and global champions
- Strong US foodservice demand with market share gains for bag-in-box
- High demand for broths in aseptic cartons in USA and Canada

#### 2023:

- Our first aseptic carton plant in Mexico to simplify supply chain for North America and increase customer proximity. Commercial production commenced mid-February 2023
- Category diversification into school milk with singleserve aseptic cartons (3 contracts won in 2022) in USA
- Launching spouted pouch fruit puree in Costa Rica (inline aseptic) and bag-in-box growth in Brazil



<sup>(1)</sup> At constant currency.


<sup>(2)</sup> Excluding the impact Scholle IPN acquisition.

### Financials



### Full year adjusted EBITDA bridge

### Successful implementation of price increases



### 2022 summary:


- Strong revenue growth across all product substrates
- Consolidation of bag-in-box, spouted pouch and chilled carton with margin dilution effect
- Price increases cover cost inflation with time lag and margin dilution effect
- Executed price increase of around 4.5% – better than initially guided for
- Stringent cost control measures

<sup>(1)</sup> Production includes energy and freight costs



### Resilient adjusted EBITDA margin in 2022

### Amidst intense global inflation



### 2022 margin impacted by:

- Consolidation of acquisitions
- Dilutive impact of price increases
- Not all cost inflation offset in 2022

Price increases in 2023 to continue to offset the impact of cost inflation


<sup>(2)</sup> Cost inflation not yet covered by price increase



<sup>(1)</sup> Adjusted EBITDA as % of revenue

### Resilient adjusted EBITDA margin in Q4 2022

### Amidst intense global inflation





### Q4 margin impacted by:

- Strong revenue performance of bag-in-box and spouted pouch in Q4
- Organic constant currency revenue growth of 9.8%
- Carton pricing in Q4 over 6%
- Q4 performance revenue mix driven by growth in regions impacted by highest cost inflation
- Raw material, energy and freight prices remained high throughout most of Q4



- (1) Production includes energy and freight costs
- (2) Adjusted EBITDA as % of revenue
- (3) Cost inflation not yet covered by price increases

### Free cash flow

### Strong cash generation

€ million	2022	2021
Net cash from operating activities	578	531
Acquisition of property, plant and equipment and intangible assets (net of sales) <sup>(1)</sup>	(281)	(246)
Payment of lease liabilities	(35)	(27)
Free cash flow	263	258
Net working capital	324	173
% of revenue	10.5%(2)	8.4%
Operating net working capital <sup>(3)</sup>	(236)	(253)
% of revenue	(7.6%)(2)	(12.3%)

NWC impacted by higher net working capital intensity in bag-in-box, spouted pouch and chilled carton



<sup>(1)</sup> For the year ended 31 December 2022, the Group also considers proceeds from sales of PP&E, other than filling lines and other related equipment, and intangible assets in its calculation of free cash flow. See note 11 of the consolidated financial statements.

<sup>(2)</sup> Includes the revenue of Scholle IPN and Evergreen Asia from 1 January 2022

<sup>(3)</sup> Including liabilities for volume bonuses and other incentives to customers settled in following year

### Capital expenditure

### Historic level of gross filler orders

€ million	2022	2021
Capital expenditure		
PP&E and intangible assets (net of sales and excl. filling lines and other related equipment) <sup>(1)</sup>	108	93
Filling lines and other related equipment	173	153
Upfront cash	(137)	(103)
Net capital expenditure	144	143
% of revenue	5.2%	6.9%
	5.2%	6.9%
	5.2% 1,359	6.9%
% of revenue		
% of revenue		
% of revenue  No. of aseptic fillers in the field	1,359	1,295

- Net capex 5.2% of revenue: higher proportion of contracts with upfront cash
- 91 gross filler additions reflect strong demand
- PPE includes growth investments and consolidation of bag-in-box, spouted pouch and chilled carton segments

<sup>(1)</sup> For the year ended 31 December 2022, the Group also considers proceeds from sales in its calculation of capital expenditure for PP&E (excluding filling lines and other related equipment) and intangible assets. See note 11 of the consolidated financial statements.



### Leverage and financing

High cash balance at year end; target 2.5x leverage by end of 2024 (2x mid-term)

€ million	2022(1)	<b>2021</b> <sup>(2)</sup>
Gross debt	2,684	1,732
Cash	504	305
Net debt	2,180	1,428
Net leverage ratio	3.1x	2.5x

Net debt reflects acquisition financing

€450M Eurobond maturing June 2023

- €400M bridge facility secured in January to provide flexibility to optimise timing of partial refinancing
- Looking to reduce overall gross debt during the course of the year

<sup>(2)</sup> In the calculation of the net leverage ratio as of 31 December 2021, adjusted EBITDA includes the adjusted EBITDA of the former joint ventures in the Middle East from 1 January 2021.



<sup>(1)</sup> In the calculation of the net leverage ratio as of 31 December 2022, adjusted EBITDA includes the adjusted EBITDA of Scholle IPN and Evergreen Asia from 1 January 2022

### Maintaining strong ROCE

### Post-tax ROCE 27%

€ million	<b>2022</b> <sup>(1)</sup>	2021(2)
Income statement items		
Adjusted EBITDA	709	579
Depreciation of PP&E	(206)	(172)
ROCE EBITA	502	407
Balance sheet items		
Current assets (excluding cash and cash equivalents)	908	519
Current liabilities (excluding interest-bearing liabilities)	(1,287)	(872)
PP&E	1,668	1,271
Capital employed	1,289	918
Pre-tax ROCE <sup>(3)</sup>	39.0%	44.3%
ROCE tax rate	30%	30%
Estimated post-tax ROCE <sup>(4)</sup>	27.3%	31.0%

- ROCE remains high
- Impact from acquisition offset by higher returns from organic business of 33% ROCE (post 30% tax)
- Group ROCE at adjusted effective tax rate: 29.7%
- Continue to expect ROCE to increase over mid-term as function of margin improvement and asset efficiency

<sup>(4)</sup> Post-tax ROCE is calculated by adjusting pre-tax ROCE by applying a reference tax rate of 30%



<sup>(1)</sup> In the calculation of the ROCE EBITA as of 31 December 2022, adjusted EBITDA and depreciation of PP&E includes the adjusted EBITDA and depreciation of PP&E of Scholle IPN and Evergreen Asia from 1 January 2022

<sup>(2)</sup> Including two months' MEA JV.

<sup>(3)</sup> Pre-tax return on capital employed ("ROCE") represents ROCE EBITA divided by capital employed

### Guidance and concluding remarks



### 2023 financial guidance

Revenue growth Includes organic 20-22% (constant currency) growth of 7-9% **Adjusted EBITDA** Range of +50-150 bps 24-25% margin **Adjusted effective** 26-28% tax rate **Net CAPEX** 7-9% (% revenue) Dividend payout ratio 50-60% (of adjusted net income)

- Organic<sup>(1)</sup> price increases expected to be of similar magnitude to 2022
- Resin escalator for bagin-box and spouted pouch not included in guidance
- Annualisation of M&A consolidations
- Guidance subject to input cost and forex volatility

### Mid-term financial guidance

### Unchanged

Revenue growth (constant currency)	4-6%	Upper half of range
Adjusted EBITDA margin	Above <b>27%</b>	
Net CAPEX (% revenue)	7-9%	
<b>Dividend payout ratio</b> (of adjusted net income)	50-60%	
Net leverage	Towards 2x	

- Best-in-class margins
- Strong cash generation
- Attractive pay-out policy with progressive dividend growth
- Clear path to deleveraging – around 2.5x by year end 2024



# Thank you!

